Moderate levels of alcohol consumption linked to higher risk of some cancers, NCI writes in JAMA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Even moderate levels of alcohol consumption appear to be associated with a higher risk of some cancers—including cancers of the female breast—as well as adverse cardiovascular health effects, NCI researchers wrote in JAMA.

The article, “Alcohol and Cancer: Research and Clinical Implications,” is co-authored by three associate directors in the Division of Cancer Control and Population Sciences at NCI.

The paper highlights the low awareness of the association between alcohol use and cancer and makes a call for increasing clinician knowledge and patient-provider communication regarding the effects of alcohol on cancer. The authors also supports increased focus and research on the harms of moderate drinking, in addition to the more commonly studied harms from risky drinking and alcohol use disorders.

Alcohol is associated with almost 90,000 cases of cancer of the oral cavity, throat, liver, female breast, and colorectum per year. Awareness of this relationship is low not only in the U.S., but worldwide. The paper also notes evidence that reductions in alcohol use are associated with decreased cancer mortality.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login